Ampio Amps Up on Pain Findings in Knee Osteoarthritis
By Marie Powers
Wednesday, August 14, 2013
Positive findings from an initial Phase III study of pain candidate Ampion drove shares of Ampio Pharmaceuticals Inc. (NYSE:AMPE) higher Wednesday. Patients in the Phase III SPRING study in osteoarthritis of the knee (OAK) treated with a single intra-articular injection of the non-steroidal immunomodulator achieved clinically meaningful reduction in pain.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.